tetano
Editor, Senior Moderator
Int J Biol Macromol. 2016 May 13. pii: S0141-8130(16)30457-3. doi: 10.1016/j.ijbiomac.2016.05.046. [Epub ahead of print]
[h=1]Effect of a polysaccharide from Poria cocos on humoral response in mice immunized by H1N1 influenza and HBsAg vaccines.[/h] Wu Y[SUP]1[/SUP], Li S[SUP]2[/SUP], Li H[SUP]3[/SUP], Zhao C[SUP]4[/SUP], Ma H[SUP]5[/SUP], Zhao X[SUP]6[/SUP], Wu J[SUP]7[/SUP], Liu K[SUP]8[/SUP], Shan J[SUP]9[/SUP], Wang Y[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Poria cocos has a long history of medicinal use in China. Polysaccharides and their derivatives in the medicine exhibit many beneficial biological activities including anticancer, anti-inflammatory, antioxidant and antiviral activities. In this study, a new polysaccharide (PCP-II) was isolated from sclerotium of Poria cocos. Its physico-chemical characters were identified and its adjuvant activity was investigated in mice co-immunized with H1N1 influenza vaccine and hepatitis B surface antigen (HBsAg). The results revealed that PCP-II has a molecular weight of 29.0kDa. It was composed of fucose, mannose, glucose and galactose in molar ration of 1.00: 1.63: 0.16: 6.29 respectively. Pharmacological data demonstrated that PCP-II increased antigen-specific antibody levels in mice immunized with influenza vaccine. PCP-II also elicited anti-HBsAg antibodies at significantly higher titers and generated robust and durable immunity compared to mice immunized with HBsAg-alum following two administrations. PCP-II improved proliferation of splenocytes, stimulated IL-12p70 and TNF-α productions in dendritic cells and macrophages respectively. These results suggested that PCP-II-adjuvanted vaccines enhanced humoral and cellular immunity. PCP-II could be developed as an efficacious adjuvant in human and animal vaccines.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Poria cocos; adjuvant; polysaccharide; vaccine
PMID: 27185068 [PubMed - as supplied by publisher]
[h=1]Effect of a polysaccharide from Poria cocos on humoral response in mice immunized by H1N1 influenza and HBsAg vaccines.[/h] Wu Y[SUP]1[/SUP], Li S[SUP]2[/SUP], Li H[SUP]3[/SUP], Zhao C[SUP]4[/SUP], Ma H[SUP]5[/SUP], Zhao X[SUP]6[/SUP], Wu J[SUP]7[/SUP], Liu K[SUP]8[/SUP], Shan J[SUP]9[/SUP], Wang Y[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Poria cocos has a long history of medicinal use in China. Polysaccharides and their derivatives in the medicine exhibit many beneficial biological activities including anticancer, anti-inflammatory, antioxidant and antiviral activities. In this study, a new polysaccharide (PCP-II) was isolated from sclerotium of Poria cocos. Its physico-chemical characters were identified and its adjuvant activity was investigated in mice co-immunized with H1N1 influenza vaccine and hepatitis B surface antigen (HBsAg). The results revealed that PCP-II has a molecular weight of 29.0kDa. It was composed of fucose, mannose, glucose and galactose in molar ration of 1.00: 1.63: 0.16: 6.29 respectively. Pharmacological data demonstrated that PCP-II increased antigen-specific antibody levels in mice immunized with influenza vaccine. PCP-II also elicited anti-HBsAg antibodies at significantly higher titers and generated robust and durable immunity compared to mice immunized with HBsAg-alum following two administrations. PCP-II improved proliferation of splenocytes, stimulated IL-12p70 and TNF-α productions in dendritic cells and macrophages respectively. These results suggested that PCP-II-adjuvanted vaccines enhanced humoral and cellular immunity. PCP-II could be developed as an efficacious adjuvant in human and animal vaccines.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Poria cocos; adjuvant; polysaccharide; vaccine
PMID: 27185068 [PubMed - as supplied by publisher]